We initiate formal coverage of Oncimmune, a leading immuno-diagnostic developer that uses its proprietary autoantibody technology to profile the body’s natural response to cancer. Oncimmune has entered an exciting stage of its development with the lead EarlyCDT Lung test poised for an NHS launch, and growing traction in the new autoantibody profiling ImmunoINSIGHTS platform. We introduce our base case forecasts, showing a clear growth path to profitability and potential for outperformance.
30 Oct 2020
A growth platform - Initiation and FY20 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A growth platform - Initiation and FY20 results
Oncimmune Holdings Plc (ONC:LON) | 29.1 1 13.6% | Mkt Cap: 21.6m
- Published:
30 Oct 2020 -
Author:
Edward Thomason -
Pages:
3
We initiate formal coverage of Oncimmune, a leading immuno-diagnostic developer that uses its proprietary autoantibody technology to profile the body’s natural response to cancer. Oncimmune has entered an exciting stage of its development with the lead EarlyCDT Lung test poised for an NHS launch, and growing traction in the new autoantibody profiling ImmunoINSIGHTS platform. We introduce our base case forecasts, showing a clear growth path to profitability and potential for outperformance.